all

The NLA has released a statement paper that provides updated guidance to clinicians to help identify patient groups in whom treatment with PCSK9 monoclonal antibodies (mAbs) provides a reasonable value.

Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the U.S. Food and Drug Administraion (FDA) has approved Praluent®  (alirocumab) to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization in adults with established cardiovascular (CV) disease.  

WAYLIVRA, the only therapy available for Familial Chylomicronemia Syndrome (FCS), has been authorized as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis whose response to diet and triglyceride-lowering therapy has been inadequate, according to a May 7 press release issued by Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.